Griffith University Researchers Reveal COVID-19's Lasting Impact on Brain Tissue

Griffith University researchers have made a groundbreaking discovery that sheds new light on the enduring neurological consequences of COVID-19. Using cutting-edge multimodal magnetic resonance imaging (MRI) techniques, scientists at the university's National Centre for Neuroimmunology and Emerging Diseases (NCNED) identified measurable alterations in brain tissue microstructure and neurochemical profiles. These changes persist not only in individuals grappling with long COVID but also in those who have seemingly fully recovered from the infection. This finding underscores the virus's subtle yet profound influence on brain health, even when symptoms have resolved.

The study highlights how SARS-CoV-2, the virus responsible for COVID-19, can leave an indelible mark on the central nervous system. Grey and white matter regions essential for memory, cognition, and overall brain function showed distinct differences when compared to healthy controls who never contracted the virus. Such insights are particularly relevant in Australia, where long COVID affects a significant portion of the population, prompting universities to ramp up research efforts in neuroimmunology and related fields.

🧠 Advanced MRI Techniques Unlock Hidden Brain Changes

To uncover these alterations, the Griffith team employed a 3T MRI scanner equipped with multiple imaging modalities. T1-weighted and T2-weighted (T1w/T2w) imaging provided insights into myelin integrity—a crucial component of white matter that facilitates rapid nerve signal transmission. Diffusion-weighted imaging (DWI) revealed microstructural details, such as changes in water molecule movement within tissues, which can indicate inflammation or damage. Magnetic resonance spectroscopy (MRS) measured levels of key neurochemicals like gamma-aminobutyric acid (GABA) and glutamate (Glu), which play pivotal roles in neuronal excitation and inhibition.

This comprehensive approach allowed for a nuanced comparison across three groups: patients with long COVID (defined as persistent symptoms beyond 12 weeks post-infection), individuals recovered from COVID-19 who reported no ongoing issues, and healthy controls. The rigorous methodology, approved by Griffith's Human Research Ethics Committee, ensured high reliability, setting a new standard for neuroimaging studies in Australian higher education research.

Microstructural Shifts: Evidence of Lasting Tissue Remodeling

The most striking results emerged from T1w/T2w signal analysis, which indicated disrupted myelin signals across all COVID-affected groups compared to controls. DWI metrics further confirmed altered tissue microstructure, suggesting subtle remodeling or gliosis—where supportive glial cells proliferate in response to injury. These changes were not confined to long COVID patients; recovered individuals exhibited similar patterns, implying that the virus triggers persistent biological shifts even without clinical symptoms.

In practical terms, such microstructural alterations could underlie subtle cognitive hiccups, like momentary lapses in focus or recall, that many post-COVID Australians experience. Griffith's findings align with global trends but provide Australia-specific data, bolstering the case for sustained university-led investigations into viral neuropathology.

Neurochemical Imbalances: A Marker for Symptom Severity

While microstructural changes were widespread, neurochemical disruptions were more pronounced in long COVID patients. MRS data showed imbalances in excitatory and inhibitory neurotransmitters, correlating directly with symptom severity. For instance, higher fatigue and cognitive complaints aligned with aberrant GABA and glutamate levels, pointing to dysregulated neural signaling.

This correlation is crucial for clinicians and underscores the need for targeted interventions. In the context of Australian higher education, NCNED's expertise positions Griffith as a hub for translating these biomarkers into diagnostic tools, potentially aiding thousands affected by long COVID nationwide.

Griffith's NCNED: Pioneering Neuroimmunology in Australia

At the heart of this research is Griffith University's NCNED, directed by Professor Sonya Marshall-Gradisnik. The centre brings together multidisciplinary experts, including lead researcher Dr. Kiran Thapaliya, Maira Inderyas, and Leighton Barnden, who specialize in neuroimaging and neuroimmunology. Established to tackle complex conditions like myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and now long COVID, NCNED leverages state-of-the-art facilities to drive transformative discoveries.

"We are privileged to access state-of-the-art technologies which drive transformative scientific discoveries," notes Professor Marshall-Gradisnik. This hub not only advances knowledge but also trains the next generation of researchers, fostering careers in neuroimaging and viral neurology within Australia's vibrant higher education landscape.

Photo by Natalie Parham on Unsplash

Parallels with ME/CFS: Overlapping Neurological Pathways

Griffith's work reveals striking similarities between long COVID and ME/CFS, conditions often sharing symptoms like profound fatigue and brain fog. Recent NCNED studies using 7 Tesla ultra-high-field MRI identified enlarged hippocampal volumes—a brain region vital for memory—in both groups. Another investigation showed reduced connectivity during cognitive tasks, explaining slowed thinking and concentration issues.

These overlaps suggest shared pathophysiological mechanisms, possibly involving neuroinflammation or immune dysregulation. For Australian universities, this convergence opens doors for collaborative grants, enhancing research capacity in post-viral syndromes.

Australian Context: Prevalence and Research Momentum

Long COVID affects an estimated 5-10% of Australians post-infection, with higher rates in vulnerable groups. The economic burden, including lost productivity, rivals major chronic diseases. Griffith's study contributes to a growing body of Australian research, supported by Medical Research Future Fund (MRFF) grants totaling millions for long COVID initiatives at universities like UNSW and La Trobe.

This national effort highlights higher education's role in addressing public health challenges, from biomarker discovery to clinical trials. As prevalence data evolves—potentially impacting 1 in 10 Australians—universities are pivotal in developing management strategies.

Implications for Patient Care and Policy

Beyond academia, these findings advocate for routine neuroimaging in persistent post-COVID cases. Altered brain metrics could guide personalized therapies, such as neurorehabilitation or anti-inflammatory treatments. In Australia, where long COVID clinics are expanding, Griffith's evidence supports policy shifts toward long-term neurological monitoring.

For educators and researchers, it emphasizes interdisciplinary training, blending immunology, neuroimaging, and clinical practice—core strengths in Australian colleges and universities.

Future Research Horizons at Griffith and Beyond

NCNED plans longitudinal studies tracking brain recovery and trials for neuroprotective interventions. Collaborations with other Australian institutions promise expanded cohorts and advanced 7T MRI access. Emerging questions include vaccination's protective effects and genetic predispositions.

This trajectory positions Griffith at the forefront, attracting funding and talent to Queensland's higher education ecosystem.

Careers in Neuroimaging: Opportunities Down Under

The surge in long COVID research fuels demand for neuroimaging specialists, research assistants, and neuroimmunologists. Griffith and peer universities offer roles in MRI analysis, clinical trials, and data science. With Australia's robust research funding, these positions provide pathways for PhD students and postdocs to contribute meaningfully.

Explore openings in research jobs across Australian universities, where expertise in brain health meets global challenges.

Photo by Chris Andrawes on Unsplash

As Griffith University's pioneering work demonstrates, COVID-19's brain legacy demands ongoing vigilance and innovation. Australian higher education stands ready to lead, translating discoveries into better outcomes for patients and society. Stay informed and consider how these insights shape the future of neurological research and care.